FDA Grants Priority Review Status to Prevnar 13 Marketing Application
Collegeville, Pennsylvania (ots/PRNewswire) - -- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) granted priority review to the company's Biologic License Application ...